|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.
|
20185823 |
2010 |
|
Breast Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.
|
20185823 |
2010 |
|
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
CTD_human |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Breast Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Breast Carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Quantitative RT-PCR demonstrated that six genes from the combined signatures (CXCL9, ITSN2, GNAI2, H2AFX, INDO, and MGC10986) were significantly differentially expressed in the recurrence versus the non-recurrence group of the 19 cases and the independent breast cancer patient cohort (n = 51) treated with CMF.
|
18925433 |
2009 |
|
Neoplasm Recurrence, Local
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
|
18925433 |
2009 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Bioinformatics analysis and luciferase reporter gene assay data further confirmed that LIMD2 was a direct target gene of microRNA-124 (miR-124), a well-known tumor suppressor in NSCLC.
|
31423280 |
2019 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that LIMD2 may play an important role in the metastatic process of PTC, predominantly in BRAF V600E-positive tumors.
|
29560564 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In this work, we characterize LIMD2, a mechanistically undefined LIM-only protein originally found to be overexpressed in metastatic lesions but absent in the matched primary tumor.
|
24590809 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
LIMD2 and PTPRC (CD45) showed a statistically significant difference in expression between tumor and metastatic samples (P < 0.0045), and an additional gene (LTB) had borderline significance.
|
17699795 |
2007 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The knockdown of LIMD2 caused remarkable decreases in NSCLC cell proliferation, migration and invasion.
|
31423280 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells.
|
30221696 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
This strongly suggests that LIMD2 potentiates its biologic effects through direct interactions with ILK, a signal transduction pathway firmly linked to cell motility and invasion.
|
24590809 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Bioinformatics analysis and luciferase reporter gene assay data further confirmed that LIMD2 was a direct target gene of microRNA-124 (miR-124), a well-known tumor suppressor in NSCLC.
|
31423280 |
2019 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
LIM domain containing 2 (LIMD2) is a small LIM-only protein that has been demonstrated to promote tumor progression; however, the expression and function of LIMD2 in non-small cell lung cancer (NSCLC) has not previously been reported.
|
31423280 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, the high expression of LIMD2 was significantly associated with lymph node metastasis, distant metastasis and advanced clinical stage in NSCLC.
|
31423280 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the present study reported an inverse correlation between the expression of LIMD2 and miR‑34a in NSCLC tissues.
|
30221696 |
2018 |
|
melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A previous study indicated that LIM domain containing 2 (LIMD2) is an oncogene in a variety of human cancers, including breast, bladder and thyroid cancers, and melanoma; however, the role of LIMD2 in non‑small cell lung cancer (NSCLC) remains largely unknown.
|
30221696 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, in eight cases, the staining intensity of LIMD2 was stronger in the patient-matched lymph node metastases than in the primary tumors.
|
29560564 |
2018 |
|
melanoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
LIMD2 levels in fresh and archival tumors positively correlate with cell motility, metastatic potential, and grade, including bladder, melanoma, breast, and thyroid tumors.
|
24590809 |
2014 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.
|
24590809 |
2014 |